SecSonar.com

Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Supernus Pharmaceuticals, Inc. (SUPN) is a Drug Manufacturers - Specialty & Generic company based in US with a market capitalization of $2.7B. Revenue grew 8.6% year-over-year and the company generated $46M in free cash flow. This page tracks SUPN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 674 employees · IPO May 1, 2012

Valuation

Valuation & price

$49.43 · as of May 17, 2026 · -13.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.54

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$57.00$44.23$31.45Jul 25Dec 25Jul 26Jul 7, 25$31.45Jul 9, 25$32.67Jul 11, 25$33.12Jul 15, 25$33.51Jul 17, 25$33.59Jul 21, 25$33.23Jul 23, 25$32.97Jul 25, 25$33.58Jul 29, 25$33.45Jul 31, 25$35.10Aug 4, 25$37.05Aug 6, 25$42.44Aug 11, 25$40.57Aug 13, 25$42.64Aug 15, 25$42.69Aug 19, 25$42.00Aug 21, 25$43.32Aug 25, 25$44.43Aug 27, 25$45.07Aug 29, 25$45.12Sep 3, 25$44.93Sep 5, 25$46.00Sep 9, 25$46.03Sep 11, 25$46.66Sep 16, 25$43.99Sep 18, 25$46.13Sep 22, 25$46.98Sep 24, 25$47.10Sep 26, 25$47.03Sep 30, 25$47.79Oct 2, 25$47.96Oct 6, 25$48.31Oct 8, 25$48.00Oct 10, 25$49.00Oct 14, 25$49.22Oct 16, 25$49.76Oct 21, 25$50.67Oct 23, 25$52.02Oct 27, 25$52.72Oct 29, 25$55.68Oct 31, 25$55.13Nov 4, 25$57.00Nov 6, 25$47.27Nov 10, 25$45.40Nov 12, 25$44.62Nov 14, 25$45.00Nov 18, 25$44.90Nov 20, 25$44.79Nov 25, 25$46.08Nov 28, 25$45.59Dec 2, 25$44.12Dec 4, 25$45.10Dec 8, 25$47.16Dec 10, 25$46.16Dec 12, 25$47.16Dec 16, 25$48.32Dec 18, 25$49.28Dec 22, 25$51.50Dec 24, 25$51.77Dec 29, 25$51.25Jan 2, 26$49.47Jan 6, 26$49.26Jan 8, 26$51.17Jan 12, 26$51.36Jan 14, 26$51.80Jan 16, 26$50.00Jan 21, 26$49.52Jan 23, 26$48.25Jan 27, 26$49.44Jan 29, 26$49.06Feb 2, 26$48.78Feb 4, 26$49.08Feb 9, 26$51.30Feb 11, 26$51.34Feb 13, 26$50.84Feb 18, 26$50.20Feb 20, 26$50.86Feb 24, 26$53.30Feb 26, 26$55.75Mar 2, 26$55.09Mar 4, 26$55.58Mar 6, 26$53.87Mar 10, 26$53.67Mar 12, 26$50.46Mar 17, 26$50.82Mar 19, 26$48.84Mar 23, 26$49.25Mar 25, 26$50.06Mar 27, 26$49.52Mar 31, 26$51.69Apr 2, 26$50.48Apr 7, 26$50.96Apr 9, 26$51.50Apr 13, 26$49.95Apr 15, 26$49.94Apr 17, 26$51.39Apr 22, 26$50.29Apr 24, 26$49.76Apr 28, 26$48.69Apr 30, 26$48.00May 4, 26$48.63May 6, 26$51.45May 8, 26$51.53May 12, 26$50.53May 14, 26$51.20May 18, 26$48.33May 20, 26$48.69May 22, 26$48.21May 28, 26$46.85Jun 1, 26$44.76Jun 3, 26$44.04Jun 5, 26$44.75Jun 9, 26$45.66Jun 11, 26$45.55Jun 15, 26$43.86Jun 17, 26$43.58Jun 22, 26$44.48Jun 24, 26$45.14Jun 26, 26$46.84Jul 2, 26$48.05
$31.4552-week range$57.00
Loading valuation history…

Fundamentals

Key fundamentals

$2.7B

Market cap

8.6%

Revenue growth (YoY)

89.6%

Gross margin

$46M

Free cash flow (USD)

-$267.7M

Net debt

Net cash position

2.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$215.0MFY 2017$302.2MFY 2018$408.9MFY 2019$392.8MFY 2020$520.4MFY 2021$579.8MFY 2022$667.2MFY 2023$607.5MFY 2024$661.8MFY 2025$719.0M
$215M$719M

Free cash flow by year

2016 → 2025

FY 2016$65.2MFY 2017$112.6MFY 2018$128.1MFY 2019$140.4MFY 2020$134.9MFY 2021$125.1MFY 2022$116.4MFY 2023$110.5MFY 2024$171.2MFY 2025$46.0M
$65.2M$46M

Gross margin by year

2021 → 2025

FY 202187.0%FY 202286.9%FY 202386.2%FY 202488.2%FY 202589.6%
87.0%89.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 18, 2026Filing
  • 8-K eventMilestone Payment NotificationMay 20, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • Quarterly report10-Q FiledMay 5, 2026Filing
  • 8-K eventEarnings Release Date AnnouncedApr 22, 2026Filing
  • 8-K eventAsset Purchase AgreementApr 7, 2026Filing

Questions

Frequently asked questions

What is Supernus Pharmaceuticals, Inc.'s market cap?

Supernus Pharmaceuticals, Inc. (SUPN) has a market capitalization of $2.7B.

What is SUPN's P/E ratio?

A meaningful P/E ratio is not available for SUPN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is SUPN's price-to-book (P/B) ratio?

SUPN trades at 2.54 times book value per share.

Are insiders buying SUPN stock?

SEC Form 4 filings show no open-market insider buys at Supernus Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Drug Manufacturers - Specialty & Generic

HCM

HUTCHMED (China) Limited

$2B

BHC

Bausch Health Companies Inc.

$2B

ANIP

ANI Pharmaceuticals, Inc.

$1.8B

PRGO

Perrigo Company plc

$1.6B

HROW

Harrow Health, Inc.

$1.3B

PAHC

Phibro Animal Health Corporation

$1.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.